Proposal of combination therapies to treat refractory chronic migraine

Vol. 33 No. 3 (2023)
Published: 15 December 2023
chronic migraine, onabotulinumtoxin A, anti-CGRP monoclonal antibodies, atogepant
Abstract Views: 115
PDF: 57
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Damiana Scuteri
damiana.scuteri@unical.it
Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende; Regional Center for Serious Brain Injuries, S. Anna Institute, Crotone, Italy.
Martina Pagliaro
Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende; Regional Center for Serious Brain Injuries, S. Anna Institute, Crotone, Italy.
Andrea Monteleone
Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
Assunta Tarsitano
Provincial Health Authority (ASP), Cosenza, Italy.
Rosario Iannacchero
Department Neurology Headache Center, Hospital Regional “Pugliese-Ciaccio”, Catanzaro, Italy.
Marilù Vulnera
Provincial Health Authority (ASP), Cosenza, Italy.
Giorgio Sandrini
Department of Brain and Behavioral Sciences, University of Pavia, IRCCS C. Mondino Foundation Neurologic Institute, Pavia, Italy.
Paolo Tonin
Regional Center for Serious Brain Injuries, S. Anna Institute, Crotone, Italy.
Giacinto Bagetta
Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
Maria Tiziana Corasaniti
Department of Health Sciences, University “Magna Graecia” of Catanzaro, Italy.

Chronic migraine, affecting people for over 15 days per month of which 8 show migraine features, severely reduces patients’ quality of life with great rate of associated disability. Onabotulinumtoxin A has been used in the prevention of chronic migraine for the last two decades. A recent pooled analysis of real-world data highlighted the efficacy of its use in combination with the most novel monoclonal antibodies targeting the machinery of the calcitonin gene-related peptide (CGRP) in refractory migraine. Moreover, the CRD42023393250 systematic review and meta-analysis registered in the National Institute for Health Research International prospective register of systematic reviews PROSPERO following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 statement supported the safety of onabotulinumtoxin A, demonstrating that it induces fewer treatment-related adverse events (TRAEs) than oral topiramate one of the most commonly used preventative drugs. Therefore, the present data together with the lack of appropriately designed, prospective studies prompt the proposal of clinical trials to assess the efficacy and safety of the combination treatment of onabotulinumtoxinA with monoclonal antibodies or gepants directed towards the pathway of CGRP.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

1.
Scuteri D, Pagliaro M, Monteleone A, Tarsitano A, Iannacchero R, Vulnera M, et al. Proposal of combination therapies to treat refractory chronic migraine. Confinia Cephalal [Internet]. 2023 Dec. 15 [cited 2025 Jan. 22];33(3):e2023020. Available from: https://www.confiniacephalalgica.com/site/article/view/15277
Copyright (c) 2023 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.


Most read articles by the same author(s)